ACUTAAS

Acutaas Chemicals Share Price

 

 

Invest in Acutaas Chemicals with 2.86X leverage

Invest with MTF

Performance

  • Low
  • ₹1,733
  • High
  • ₹1,765
  • 52 Week Low
  • ₹919
  • 52 Week High
  • ₹1,902
  • Open Price₹1,737
  • Previous Close₹1,751
  • Volume103,613

Investment Returns

  • Over 1 Month -1.53%
  • Over 3 Month + 26.44%
  • Over 6 Month + 55.69%
  • Over 1 Year + 67.53%

Smart Investing Starts Here Start SIP with Acutaas Chemicals for Steady Growth!

Invest Now

Acutaas Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 63.8
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 14,300
  • P/B Ratio
  • 10.1
  • Average True Range
  • 57.53
  • EPS
  • 27.36
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -9.56
  • RSI
  • 58.81
  • MFI
  • 72.18

Acutaas Chemicals Financials

Acutaas Chemicals Technicals

EMA & SMA

Current Price
₹1,746.70
-4.1 (-0.23%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,686.18
  • 50 Day
  • ₹1,664.64
  • 100 Day
  • ₹1,572.64
  • 200 Day
  • ₹1,413.04

Resistance and Support

1738.83 Pivot Speed
  • R3 1,856.27
  • R2 1,813.13
  • R1 1,781.97
  • S1 1,707.67
  • S2 1,664.53
  • S3 1,633.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ami Organics Ltd. is a leading manufacturer of specialty chemicals and pharmaceutical intermediates, serving global pharmaceutical companies. With advanced R&D and manufacturing facilities, it focuses on developing high-quality, innovative solutions for diverse therapeutic areas.

Acutaas Chemicals Ltd has an operating revenue of Rs. 1,096.90 Cr. on a trailing 12-month basis. An annual revenue growth of 41% is outstanding, Pre-tax margin of 21% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 25% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 131 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Acutaas Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-17 Quarterly Results
2025-07-30 Quarterly Results
2025-05-02 Audited Results & Final Dividend
2025-02-21 Stock Split
2025-01-28 Quarterly Results
Date Purpose Remarks
2025-09-18 FINAL Rs.1.50 per share(30%)Final Dividend
2024-09-13 FINAL Rs.3.00 per share(30%)Final Dividend
2023-09-18 FINAL Rs.3.00 per share(30%)Final Dividend
2022-08-01 FINAL Rs.3.00 per share(30%)Final Dividend
View Acutaas Chemicals Dividend History Arrow
Date Purpose Remarks
2025-04-25 Split Rs.0.00 split from Rs. 10/- to Rs. 5/-/

Acutaas Chemicals F&O

Acutaas Chemicals Shareholding Pattern

32.66%
15.81%
4.84%
16.84%
22.79%
7.06%

Acutaas Chemicals FAQs

Acutaas Chemicals share price is ₹1,746 As on 02 January, 2026 | 12:03

The Market Cap of Acutaas Chemicals is ₹14300.4 Cr As on 02 January, 2026 | 12:03

The P/E ratio of Acutaas Chemicals is 63.8 As on 02 January, 2026 | 12:03

The PB ratio of Acutaas Chemicals is 10.1 As on 02 January, 2026 | 12:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23